Otsuka to acquire antibody developer Visterra in $430M deal by Conor Hale Wednesday, July 11, 2018 Otsuka plans to acquire Visterra and its antibody engineering platform for $430 million in cash, as it aims to build out its discovery efforts.
Vir allies with Alnylam, others to build infectious disease pipeline by Arlene Weintraub Wednesday, October 18, 2017 Startup Vir Biotechnology, guided by former Biogen CEO George Scangos, is unveiling a multifaceted pipeline of treatments for infectious diseases.
Visterra adds $24M to series C to take flu drug to phase 2b by Nick Paul Taylor Thursday, October 5, 2017 The extension puts Visterra back on the multifront path through the clinic it plotted out before its aborted IPO attempt.
Visterra snags contract to start recovery from IPO misstep by Nick Paul Taylor Thursday, March 30, 2017 Visterra has begun efforts to bounce back from its failed IPO attempt by securing a contract from CARB-X.
Tocagen seeks $86M IPO to fund cancer gene therapy trial by Nick Paul Taylor Friday, March 10, 2017 Tocagen has filed to raise up to $86 million in an IPO to take its brain cancer gene therapy combination through the first part of a phase 2/3 trial.
